HK1137931A1 - Long term 24 hour intestinal administration of levodopa/carbidopa 24 / - Google Patents

Long term 24 hour intestinal administration of levodopa/carbidopa 24 /

Info

Publication number
HK1137931A1
HK1137931A1 HK10103896.7A HK10103896A HK1137931A1 HK 1137931 A1 HK1137931 A1 HK 1137931A1 HK 10103896 A HK10103896 A HK 10103896A HK 1137931 A1 HK1137931 A1 HK 1137931A1
Authority
HK
Hong Kong
Prior art keywords
carbidopa
levodopa
long term
intestinal administration
hour
Prior art date
Application number
HK10103896.7A
Other languages
English (en)
Chinese (zh)
Inventor
‧尼霍姆
‧阿斯伯格
‧博爾蘇伊
‧圖奇克-塞特勒
Original Assignee
雅培產品有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 雅培產品有限公司 filed Critical 雅培產品有限公司
Publication of HK1137931A1 publication Critical patent/HK1137931A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Dispersion Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
HK10103896.7A 2006-05-31 2010-04-21 Long term 24 hour intestinal administration of levodopa/carbidopa 24 / HK1137931A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US80988906P 2006-05-31 2006-05-31
PCT/EP2007/055275 WO2007138086A1 (en) 2006-05-31 2007-05-31 Long term 24 hour intestinal administration of levodopa/carbidopa

Publications (1)

Publication Number Publication Date
HK1137931A1 true HK1137931A1 (en) 2010-08-13

Family

ID=38434843

Family Applications (1)

Application Number Title Priority Date Filing Date
HK10103896.7A HK1137931A1 (en) 2006-05-31 2010-04-21 Long term 24 hour intestinal administration of levodopa/carbidopa 24 /

Country Status (16)

Country Link
US (1) US20080051459A1 (ko)
EP (1) EP2063865A1 (ko)
JP (1) JP2009543761A (ko)
KR (1) KR20090057349A (ko)
CN (1) CN101636145B (ko)
AU (1) AU2007267135B2 (ko)
BR (1) BRPI0711882A2 (ko)
CA (1) CA2653683A1 (ko)
HK (1) HK1137931A1 (ko)
IL (1) IL195599A0 (ko)
MX (1) MX2008015339A (ko)
NO (1) NO20085418L (ko)
RU (1) RU2484815C2 (ko)
UA (1) UA95954C2 (ko)
WO (1) WO2007138086A1 (ko)
ZA (1) ZA200810834B (ko)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2252284B1 (en) 2008-02-06 2011-05-25 Wockhardt Research Centre Pharmaceutical compositions of entacapone, levodopa and carbidopa with improved bioavailability
LT2432454T (lt) 2009-05-19 2017-07-10 Neuroderm Ltd Kompozicijos, skirtos nepertraukiamam dopa dekarboksilazės inhibitorių vartojimui
NZ610911A (en) * 2010-11-15 2015-02-27 Neuroderm Ltd Continuous administration of l-dopa, dopa decarboxylase inhibitors, catechol-o-methyl transferase inhibitors and compositions for same
EP2508174A1 (en) 2011-04-06 2012-10-10 Ljiljana Sovic Brkicic Pharmaceutical composition
EP2653179B1 (en) 2012-04-17 2019-07-10 Micrel Medical Devices S.A. System for calculating and administering a drug to a patient with Parkinson's disease
MX2014014902A (es) 2012-06-05 2015-03-04 Neuroderm Ltd Composiciones que comprenden apomorfina y acidos organicos y usos de las mismas.
HRP20231716T1 (hr) 2014-03-13 2024-03-15 Neuroderm Ltd. Pripravci inhibitora dopa dekarboksilaze
US10258585B2 (en) 2014-03-13 2019-04-16 Neuroderm, Ltd. DOPA decarboxylase inhibitor compositions
US10071069B2 (en) 2014-09-04 2018-09-11 Lobsor Pharmaceuticals Aktiebolag Pharmaceutical compositions comprising levodopa, a dopamine decarboxylase inhibitor and a COMT inhibitor and method of administration thereof
RU2743347C2 (ru) * 2014-10-21 2021-02-17 Эббви Инк. Пролекарства карбидопа и l-dopa и их применение для лечения болезни паркинсона
MA41377A (fr) * 2015-01-20 2017-11-28 Abbvie Inc Gel intestinal de lévodopa et de carbidona et procédés d'utilisation
CN113197851A (zh) 2015-05-06 2021-08-03 辛纳吉勒公司 包含药物粒子的药用悬浮液、用于其配给的装置、以及其使用方法
US10555922B2 (en) 2015-09-04 2020-02-11 Lobsor Pharmaceuticals Aktiebolag Method of treating a dopamine related disorder in a subject by administering levodopa, in combination with a dopamine decarboxylase inhibitor and a catechol-o-methyltransferase inhibitor
EP3487479A1 (en) * 2016-07-20 2019-05-29 AbbVie Inc. Levodopa and carbidopa intestinal gel and methods of use
EP3500246B1 (en) 2016-08-18 2021-08-04 Ilko Ilaç Sanayi Ve Ticaret Anonim Sirketi Antiparkinson tablet formulation with improved dissolution profile
EP3758754A1 (en) 2018-03-02 2021-01-06 Chiesi Farmaceutici S.p.A. A pharmaceutical formulation for intraduodenal administration comprising melevodopa and carbidopa
KR20200136008A (ko) 2018-03-23 2020-12-04 롭서 파마슈티컬스 악티에볼라그 신경퇴행성 장애의 치료를 위한 약제학적 조성물의 연속 투여
CA3095341A1 (en) * 2018-03-29 2019-10-03 Avion Pharmaceuticals, Llc Levodopa fractionated dose composition and use
US11389398B2 (en) 2019-05-14 2022-07-19 Clexio Biosciences Ltd. Gastroretentive treatment of nocturnal symptoms and morning akinesia in subjects with parkinson's disease
US11844754B2 (en) 2020-11-17 2023-12-19 Neuroderm, Ltd. Methods for treatment of Parkinson's disease
US11331293B1 (en) 2020-11-17 2022-05-17 Neuroderm, Ltd. Method for treatment of Parkinson's disease
US11213502B1 (en) 2020-11-17 2022-01-04 Neuroderm, Ltd. Method for treatment of parkinson's disease
WO2023126945A1 (en) * 2022-01-03 2023-07-06 Neuroderm, Ltd. Methods and compositions for treating parkinson's disease

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9203594D0 (sv) * 1992-11-30 1992-11-30 Christer Nystroem Laekemedel i dispersa system
US6166081A (en) * 1997-10-09 2000-12-26 Kushnir; Moshe Methods and apparatus for treatment of Parkinson's disease
EP1305021A4 (en) * 2000-06-23 2009-09-23 Teva Pharma RAPID EXPANSION COMPOSITION FOR GASTRIC RETENTION AND REGULATED RELEASE OF THERAPEUTIC AGENTS, AND DOSAGE FORMS COMPRISING THE SAME
FR2829027A1 (fr) * 2001-08-29 2003-03-07 Aventis Pharma Sa Association avec un antagoniste du recepteur cb1, les compositions pharmaceutiques les contenant et leur utilisation pour le traitement de la maladie de parkinson
US20060013875A1 (en) * 2002-05-29 2006-01-19 Impax Laboratories, Inc. Combination immediate release controlled release levodopa/carbidopa dosage forms
ITMI20030827A1 (it) * 2003-04-18 2004-10-19 Unihart Corp Composizione farmaceutica contenente l'associazione levodopa/carbidopa.
WO2005042101A1 (en) * 2003-10-20 2005-05-12 Teva Pharmaceutical Industries Ltd. Composition and dosage form for sustained effect of levodopa
JP4781352B2 (ja) * 2004-06-04 2011-09-28 ゼノポート，インコーポレーテッド レボドパプロドラッグおよびその組成物ならびにその使用
WO2006044202A2 (en) * 2004-10-19 2006-04-27 State Of Oregon Acting By And Through The State Board Of Higher Education On Behalf Of Oregon State University Enteric coated compositions that release active ingredient(s) in gastric fluid and intestinal fluid
WO2007002516A2 (en) * 2005-06-23 2007-01-04 Spherics, Inc. Improved dosage forms for movement disorder treatment
EP1945188A2 (en) * 2005-11-07 2008-07-23 Teva Pharmaceutical Industries Ltd. Levodopa compositions

Also Published As

Publication number Publication date
WO2007138086A1 (en) 2007-12-06
AU2007267135B2 (en) 2013-03-07
UA95954C2 (ru) 2011-09-26
ZA200810834B (en) 2010-03-31
CA2653683A1 (en) 2007-12-06
EP2063865A1 (en) 2009-06-03
JP2009543761A (ja) 2009-12-10
RU2008150776A (ru) 2010-07-10
CN101636145A (zh) 2010-01-27
AU2007267135A1 (en) 2007-12-06
IL195599A0 (en) 2009-09-01
KR20090057349A (ko) 2009-06-05
RU2484815C2 (ru) 2013-06-20
NO20085418L (no) 2009-02-26
BRPI0711882A2 (pt) 2012-01-10
US20080051459A1 (en) 2008-02-28
MX2008015339A (es) 2008-12-16
CN101636145B (zh) 2014-04-23

Similar Documents

Publication Publication Date Title
HK1137931A1 (en) Long term 24 hour intestinal administration of levodopa/carbidopa 24 /
IL175314A0 (en) Administration of levodopa and carbidopa
EP1987068A4 (en) MODIFICATION OF OLIGOSACCHARIDES AND MARKING OF PROTEINS
EP2104424A4 (en) PHARMACEUTICAL COMPOSITIONS COMPRISING ENTACAPONE, LEVODOPA, AND CARBIDOPA
EP1924318A4 (en) SYNCHRONIZATION OF REPETITIVE THERAPEUTIC INTERVENTIONS
GB0604535D0 (en) Betulonic acid derivatives
PL1994004T3 (pl) 1,4-Dipodstawione pochodne 3-cyjano-pirydonu i ich zastosowanie jako pozytywnych allosterycznych modulatorów receptorów MGLUR2
EP2068864A4 (en) THERAPEUTIC USES OF UROLITHINS
IL193473A0 (en) Amide derivatives and their application for the treatment of g protein related diseases
ZA200700993B (en) Infusion and injection solution of levodopa
GB2436421B (en) Timing source
WO2011044230A9 (en) N-acetylcysteine amide (nac amide) for the treatment of diseases and conditions
EP2120965A4 (en) N-HALOGENATED AMINO BINDINGS AND DERIVATIVES
GB0622834D0 (en) Timing source
IL198513A0 (en) Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives
HRP20130544T1 (en) Long term treatment of hiv- infection with tcm278
IL194189A0 (en) Combination treatment of metabolic disorders
IL193687A0 (en) Formulations of sitaxsentan sodium
EP2114374A4 (en) PHARMACEUTICAL COMPOSITIONS OF ENTACAPONE
ZA200800348B (en) Derivatives of seleno-amino acids
TWI372762B (en) Amino derivatives of b-homoandrostanes and b-heteroandrostanes
IL196320A0 (en) Derivatives and analogs of n-ethylquinolones and n-ethylazaquinolones
IL187732A0 (en) Levodopa compositions
GB0601688D0 (en) Cuff fasteners
AU2007905974A0 (en) Treatment of metabolic disease 1